INTRODUCTION: We conducted a pilot project to test the hypothesis that decreasing insulin concentrations with diazoxide would affect parameters of vitamin D in obese women with and without polycystic ovary syndrome (PCOS). MATERIALS AND METHODS: Eight obese women with PCOS and nine matched controls participated in the study. Diazoxide was administered orally 100 mg three times daily for 10 days, and parameters of vitamin D were measured at baseline and end-of-study. RESULTS: At baseline, women with polycystic ovary syndrome had significantly lower serum 25-hydroxyvitamin D (25[OH]D) levels than controls. After treatment with diazoxide, there were no significant changes in vitamin D parameters when PCOS and control women were evaluated separately. Diazoxide exhibited differential effects on 25(OH)D concentrations in PCOS as compared with normal women (P for interaction=0.045), and serum 25(OH)D levels converged after diazoxide treatment. CONCLUSIONS: Obese women with PCOS had significantly lower serum 25(OH)D levels at baseline than age- and body mass index-matched controls. Short-term administration with diazoxide seemed to have differential effects on 25(OH)D levels in PCOS as compared with control women. Further studies are necessary to confirm this finding.
INTRODUCTION: We conducted a pilot project to test the hypothesis that decreasing insulin concentrations with diazoxide would affect parameters of vitamin D in obesewomen with and without polycystic ovary syndrome (PCOS). MATERIALS AND METHODS: Eight obesewomen with PCOS and nine matched controls participated in the study. Diazoxide was administered orally 100 mg three times daily for 10 days, and parameters of vitamin D were measured at baseline and end-of-study. RESULTS: At baseline, women with polycystic ovary syndrome had significantly lower serum 25-hydroxyvitamin D (25[OH]D) levels than controls. After treatment with diazoxide, there were no significant changes in vitamin D parameters when PCOS and control women were evaluated separately. Diazoxide exhibited differential effects on 25(OH)D concentrations in PCOS as compared with normal women (P for interaction=0.045), and serum 25(OH)D levels converged after diazoxide treatment. CONCLUSIONS:Obesewomen with PCOS had significantly lower serum 25(OH)D levels at baseline than age- and body mass index-matched controls. Short-term administration with diazoxide seemed to have differential effects on 25(OH)D levels in PCOS as compared with control women. Further studies are necessary to confirm this finding.
Authors: S Hahn; U Haselhorst; S Tan; B Quadbeck; M Schmidt; S Roesler; R Kimmig; K Mann; O E Janssen Journal: Exp Clin Endocrinol Diabetes Date: 2006-11 Impact factor: 2.949
Authors: J E Nestler; C O Barlascini; D W Matt; K A Steingold; S R Plymate; J N Clore; W G Blackard Journal: J Clin Endocrinol Metab Date: 1989-06 Impact factor: 5.958
Authors: E S Knochenhauer; T J Key; M Kahsar-Miller; W Waggoner; L R Boots; R Azziz Journal: J Clin Endocrinol Metab Date: 1998-09 Impact factor: 5.958
Authors: Erin M Davis; Jennifer D Peck; Karl R Hansen; Barbara R Neas; LaTasha B Craig Journal: Minerva Endocrinol Date: 2018-04-12 Impact factor: 2.184
Authors: Nasira M Lone; Saba Riaz; Amna Z Eusaph; Charles A Mein; Eva L Wozniak; Theodoros Xenakis; Zhenqiang Wu; Sidra Younis; David A Jolliffe; Kashaf Junaid; Adrian R Martineau Journal: Sci Rep Date: 2020-02-10 Impact factor: 4.379